Tarsus Pharmaceuticals, Inc. (TARS) Revenue by Segment & Business Profile
Product was 89.7% of Tarsus Pharmaceuticals, Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TARSTarsus Pharmaceuticals, Inc.Follow TARS — free
—
Price chart with a free account
- Market cap
- 3.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What the company does
Tarsus Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (90%), License And Collaboration (10%). Trailing twelve-month revenue: $606.3 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Tarsus Pharmaceuticals, Inc. — questions
- What does Tarsus Pharmaceuticals, Inc. do?
- Tarsus Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Product (90%), License And Collaboration (10%). Trailing twelve-month revenue: $606.3 million as of 2026-06-30.
- How does Tarsus Pharmaceuticals, Inc. make money?
- By the lines it reports in its SEC filings: Product 89.7%, License And Collaboration 10.3% of revenue.
Every figure on this page comes from Tarsus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.